| abstract |
Increased in constant due to the presence of an IgG constant domain or FcRn binding portion thereof having one or more amino acid modifications that increase the affinity of the IgG constant domain or FcRn binding fragment thereof for FcRn (Fc Receptor-neonate) Providing molecules, including IgG, non-IgG immunoglobulins, proteins and non-protein substances, that have a half-life in vivo. A modified IgG comprising a human IgG constant domain with amino acid substitutions at amino acid residues 308, 309 and 311 based on Kabat's EU numbering relative to the corresponding IgG comprising a wild type human IgG CH2 domain Wherein said modified IgG has an increased half-life compared to the half-life of the corresponding IgG comprising a wild-type human IgG CH2 domain. [Selection figure] None |